We have located links that may give you full text access.
Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
BACKGROUND: Cetuximab is a chimeric human-murine monoclonal antibody against the epidermal growth factor receptor (EGFR). It has shown activities against multiple malignancies in clinical trials. EGFR-inhibitors (EGFRI) often cause skin toxicity, most frequently acneiform eruption. Xerosis, eczema, fissures, teleangiectases, nail changes and paronychia can be seen in some cases, rarely hyperpigmentation.
MATERIALS AND METHODS: We reviewed local practice of skin toxicity management during treatment with cetuximab. From November 2005 to January 2007, 31 patients with metastatic colorectal cancer were treated with cetuximab in combination with chemotherapy. They all suffered from acne-like rash. They were followed up for at least 3 months, once per week. Skin toxicity was evaluated according to NCI CTCAE, v3.0.
RESULTS: Of 31 patients, six had grade three rash, 16 patients Grade 2 and nine patients Grade 1 acne like rash. Less frequently, pruritus, dry skin, desquamation, hair modification, conjunctivitis, telangiectases, paronychia or fissures were observed. After the first documented cutaneous toxicity, topical use of emollients was started. For Grade 2 rash, we used emollients and topical antibiotics. Therapy with cetuximab was discontinued at Grade 3 until skin reactions resolved. Skin reactions at Grade 3 were generally manageable with emollients, topical and systemic antibiotics. No Grade 4 skin reactions were observed.
CONCLUSION: During the treatment with EGFRI, it is necessary to recognize and manage adverse reactions promptly to assure better patient quality of life and allowing continuation of therapy without dose reduction or drug discontinuation.
MATERIALS AND METHODS: We reviewed local practice of skin toxicity management during treatment with cetuximab. From November 2005 to January 2007, 31 patients with metastatic colorectal cancer were treated with cetuximab in combination with chemotherapy. They all suffered from acne-like rash. They were followed up for at least 3 months, once per week. Skin toxicity was evaluated according to NCI CTCAE, v3.0.
RESULTS: Of 31 patients, six had grade three rash, 16 patients Grade 2 and nine patients Grade 1 acne like rash. Less frequently, pruritus, dry skin, desquamation, hair modification, conjunctivitis, telangiectases, paronychia or fissures were observed. After the first documented cutaneous toxicity, topical use of emollients was started. For Grade 2 rash, we used emollients and topical antibiotics. Therapy with cetuximab was discontinued at Grade 3 until skin reactions resolved. Skin reactions at Grade 3 were generally manageable with emollients, topical and systemic antibiotics. No Grade 4 skin reactions were observed.
CONCLUSION: During the treatment with EGFRI, it is necessary to recognize and manage adverse reactions promptly to assure better patient quality of life and allowing continuation of therapy without dose reduction or drug discontinuation.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app